Felipe G. Serrano

Felipe G. Serrano

Auto-generated profile, based on publicly available information

Felipe G. Serrano

Centro de Envejecimiento y Regeneración (CARE), Departamento de Biología Celular y Molecular, Facultad de Ciencias Biológicas, Pontificia Universidad Católica de Chile, Santiago, Chile

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 November 2010 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
LVLorena Varela-Nallar
Lorena Varela-Nallar
IAIván E. Alfaro
Iván E. Alfaro
FSFelipe G. Serrano
Felipe G. Serrano
JPJorge Parodi
Jorge Parodi
NINibaldo Inestrosa
Nibaldo Inestrosa
Growing evidence indicates that Wingless-type (Wnt) signaling plays an important role in the maturation of the central nervous system. We report here that Wingless-type family member 5A (Wnt-5a) is expressed early in development and stimulates dendrite spine morphogenesis, inducing de novo formation of spines and increasing the size of the preexisting ones in hippocampal neurons. Wnt-5a increased intracellular calcium concentration in dendritic processes and the amplitude of NMDA spontaneous miniature currents. Acute application of Wnt-5a increased the amplitude of field excitatory postsynaptic potentials (fEPSP) in hippocampal slices, an effect that was prevented by calcium-channel blockers. The physiological relevance of our findings is supported by studies showing that Wnt scavengers decreased spine density, miniature excitatory postsynaptic currents, and fEPSP amplitude. We conclude that Wnt-5a stimulates different aspects of synaptic differentiation and plasticity in the mammalian central nervous system.

1 February 2016 in Cell Reports
Verified
Journal Article
Open access
GMGabriela Martínez
Gabriela Martínez
RVRené L. Vidal
René L. Vidal
PMPablo Mardones
Pablo Mardones
FSFelipe G. Serrano
Felipe G. Serrano
Alvaro O. ArdilesAlvaro O. Ardiles
Alvaro O. Ardiles
CHClaudio A. Hetz
Claudio A. Hetz
Contextual memory formation relies on the induction of new genes in the hippocampus. A polymorphism in the promoter of the transcription factor XBP1 was identified as a risk factor for Alzheimer's disease and bipolar disorders. XBP1 is a major regulator of the unfolded protein response (UPR), mediating adaptation to endoplasmic reticulum (ER) stress. Using a phenotypic screen, we uncovered an unexpected function of XBP1 in cognition and behavior. Mice lacking XBP1 in the nervous system showed specific impairment of contextual memory formation and long-term potentiation (LTP), whereas neuronal XBP1s overexpression improved performance in memory tasks. Gene expression analysis revealed that XBP1 regulates a group of memory-related genes, highlighting brain-derived neurotrophic factor (BDNF), a key component in memory consolidation. Overexpression of BDNF in the hippocampus reversed the XBP1-deficient phenotype. Our study revealed an unanticipated function of XBP1 in cognitive processes that is apparently unrelated to its role in ER stress.

10 March 2014 in Journal of Medicinal Chemistry
Verified
Journal Article
Open access
EVElisabet Viayna
Elisabet Viayna
ISIrene Sola
Irene Sola
MBManuela Bartolini
Manuela Bartolini
ASAngela De Simone
Angela De Simone
CTCheril Tapia-Rojas
Cheril Tapia-Rojas
Diego Muñoz-TorreroDiego Muñoz-Torrero
Diego Muñoz-Torrero
We have synthesized a family of rhein–huprine hybrids to hit several key targets for Alzheimer’s disease. Biological screening performed in vitro and in Escherichia coli cells has shown that these hybrids exhibit potent inhibitory activities against human acetylcholinesterase, butyrylcholinesterase, and BACE-1, dual Aβ42 and tau antiaggregating activity, and brain permeability. Ex vivo studies with the leads (+)- and (−)-7e in brain slices of C57bl6 mice have revealed that they efficiently protect against the Aβ-induced synaptic dysfunction, preventing the loss of synaptic proteins and/or have a positive effect on the induction of long-term potentiation. In vivo studies in APP-PS1 transgenic mice treated ip for 4 weeks with (+)- and (−)-7e have shown a central soluble Aβ lowering effect, accompanied by an increase in the levels of mature amyloid precursor protein (APP). Thus, (+)- and (−)-7e emerge as very promising disease-modifying anti-Alzheimer drug candidates.

18 December 2014 in Molecular Neurodegeneration
Verified
Journal Article
Open access
PDF file
FSFelipe G Serrano
Felipe G Serrano
CTCheril Tapia-Rojas
Cheril Tapia-Rojas
FCFrancisco J Carvajal
Francisco J Carvajal
JHJuan Hancke
Juan Hancke
Waldo CerpaWaldo Cerpa
Waldo Cerpa
NINibaldo Inestrosa
Nibaldo Inestrosa
Alzheimer’s disease (AD) is a neurodegenerative disorder in which the amyloid-β (Aβ) oligomers are a key factor in synaptic impairment and in spatial memory decline associated with neuronal dysfunction. This impairment includes synaptic failure associated with the loss of synaptic proteins that contribute to AD progression. Interestingly, the use of natural compounds is an emergent conceptual strategy in the search for drugs with therapeutic potentials for treating neurodegenerative disorders. In the present study, we report that andrographolide (ANDRO), which is a labdane diterpene extracted from Andrographis paniculata, increases slope of field excitatory postsynaptic potentials (fEPSP) in the CA1 region of hippocampal slices and inhibits long-term depression (LTD), protecting the long-term potentiation (LTP) against the damage induced by Aβ oligomers in vitro, most likely by inhibiting glycogen synthase kinase-3β (GSK-3β). Additionally, ANDRO prevents changes in neuropathology in two different age groups (7- and 12-month-old mice) of an AβPPswe/PS-1 Alzheimer’s model. ANDRO reduces the Aβ levels, changing the ontogeny of amyloid plaques in hippocampi and cortices in 7-month-old mice, and reduces tau phosphorylation around the Aβ oligomeric species in both age groups. Additionally, we observed that ANDRO recovers spatial memory functions that correlate with protecting synaptic plasticity and synaptic proteins in two different age groups. Our results suggest that ANDRO could be used in a potential preventive therapy during AD progression.

9 October 2014 in Arthritis & Rheumatology
Verified
Journal Article
Open access
PDF file
MBMarcela Bravo‐Zehnder
Marcela Bravo‐Zehnder
ETEnrique M. Toledo
Enrique M. Toledo
FSFabián Segovia‐Miranda
Fabián Segovia‐Miranda
FSFelipe G. Serrano
Felipe G. Serrano
MBMaría J. Benito
María J. Benito
AGAlfonso González
Alfonso González
Objective: To define whether anti‐ribosomal P (anti‐P) autoantibodies from patients with neuropsychiatric systemic lupus erythematosus (NPSLE) impair the function of hippocampal neurons that express the neuronal surface P antigen (NSPA) when accessing the brain via circulating blood.Methods: We used anti‐P antibodies from patients with NPSLE and rabbit‐generated anti‐P and anti‐NSPA antibodies. Primary hippocampal neurons from mice were analyzed to determine antibody cell surface binding (double immunofluorescence), intracellular calcium variations (Fura 2 AM), and apoptosis (caspase 3 activation). Hippocampal‐dependent spatial flexible memory was assessed in mice subjected to a water maze test 24 hours after an intravenous injection of anti‐P or anti‐NSPA, using lipopolysaccharide (LPS) to permeate the blood–brain barrier. Presence of antibodies and apoptosis in the hippocampus was studied using immunohistochemistry and TUNEL assays.Results: Hippocampal neurons expressed NSPA on the cell surface, as revealed by anti‐P and anti‐NSPA staining colocalization, and responded to both anti‐P and anti‐NSPA by exhibiting increased intracellular calcium levels. Neuronal apoptosis was induced when anti‐P was directly injected by stereotaxis into the hippocampus or added to primary cultures. Upon LPS treatment, intravenously injected anti‐P impaired memory but did not elicit neuronal apoptosis in the hippocampus, where it was detectable in low amounts. Anti‐NSPA antibodies also impaired memory.Conclusion: Anti‐P antibodies interact with NSPA on the surface of hippocampal neurons leading to apoptotic death or to functional perturbations, results that are likely dependent on the concentration of these antibodies. Circulating anti‐P can access the hippocampus and impair memory without requiring neuronal death when the blood–brain barrier is disrupted. NSPA can mediate antibody‐driven diffuse brain dysfunction, and anti‐P might contribute to the cognitive impairment that is frequently observed in SLE.

21 March 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LVLina M. Vargas
Lina M. Vargas
NLNancy Leal
Nancy Leal
LELisbell D. Estrada
Lisbell D. Estrada
AGAdrian González
Adrian González
FSFelipe Serrano
Felipe Serrano
Alejandra AlvarezAlejandra Alvarez
Alejandra Alvarez
The early stages of Alzheimer's disease are characterised by impaired synaptic plasticity and synapse loss. Here, we show that amyloid-β oligomers (AβOs) activate the c-Abl kinase in dendritic spines of cultured hippocampal neurons and that c-Abl kinase activity is required for AβOs-induced synaptic loss. We also show that the EphA4 receptor tyrosine kinase is upstream of c-Abl activation by AβOs. EphA4 tyrosine phosphorylation (activation) is increased in cultured neurons and synaptoneurosomes exposed to AβOs, and in Alzheimer-transgenic mice brain. We do not detect c-Abl activation in EphA4-knockout neurons exposed to AβOs. More interestingly, we demonstrate EphA4/c-Abl activation is a key-signalling event that mediates the synaptic damage induced by AβOs. According to this results, the EphA4 antagonistic peptide KYL and c-Abl inhibitor STI prevented i) dendritic spine reduction, ii) the blocking of LTP induction and iii) neuronal apoptosis caused by AβOs. Moreover, EphA4-/- neurons or sh-EphA4-transfected neurons showed reduced synaptotoxicity by AβOs. Our results are consistent with EphA4 being a novel receptor that mediates synaptic damage induced by AβOs. EphA4/c-Abl signalling could be a relevant pathway involved in the early cognitive decline observed in Alzheimer's disease patients.